• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Evolutionary conservation of influenza A PB2 sequences reveals potential target sites for small molecule inhibitors

tetano

Editor, Senior Moderator
Virology. 2017 Jun 16;509:112-120. doi: 10.1016/j.virol.2017.06.009. [Epub ahead of print]
[h=1]Evolutionary conservation of influenza A PB2 sequences reveals potential target sites for small molecule inhibitors.[/h] Patel H[SUP]1[/SUP], Kukol A[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The influenza A basic polymerase protein 2 (PB2) functions as part of a heterotrimer to replicate the viral RNA genome. To investigate novel PB2 antiviral target sites, this work identified evolutionary conserved regions across the PB2 protein sequence amongst all sub-types and hosts, as well as ligand binding hot spots which overlap with highly conserved areas. Fifteen binding sites were predicted in different PB2 domains; some of which reside in areas of unknown function. Virtual screening of ~50,000 drug-like compounds showed binding affinities of up to -10.3kcal/mol. The highest affinity molecules were found to interact with conserved residues including Gln138, Gly222, Ile529, Asn540 and Thr530. A library containing 1738 FDA approved drugs was screened additionally and revealed Paliperidone as a top hit with a binding affinity of -10kcal/mol. Predicted ligands are ideal leads for new antivirals as they were targeted to evolutionary conserved binding sites.
Copyright ? 2017. Published by Elsevier Inc.


[h=4]KEYWORDS:[/h] Binding site; Conservation; Drug discovery; Influenza A; PB2; Paliperidone; Sequence evolution; Virtual screening

PMID: 28628827 DOI: 10.1016/j.virol.2017.06.009
 
Back
Top Bottom